Improved glucose and lipid metabolism is a unique side effect of imatinib therapy in some chronic myeloid leukaemia (CML) patients. We recently reported that plasma levels of adiponectin, an important regulator of insulin sensitivity, are elevated following imatinib therapy in CML patients, which could account for these improved metabolic outcomes. Adiponectin is secreted exclusively from adipocytes, suggesting that imatinib modulates adiponectin levels directly, by transcriptional upregulation of adiponectin in pre-existing adipocytes, and/or indirectly, by stimulating adipogenesis. In this report, we have demonstrated that imatinib promotes adipogenic differentiation of human mesenchymal stromal cells (MSCs), which in turn secrete high-molecular-weight adiponectin. Conversely, imatinib does not stimulate adiponectin secretion from mature adipocytes. We hypothesise that inhibition of PDGFRa (PDGFRA) and PDGFRb (PDGFRB) is the mechanism by which imatinib promotes adipogenesis. Supporting this, functional blocking antibodies to PDGFR promote adipogenesis and adiponectin secretion in MSC cultures. We have shown that imatinib is a potent inhibitor of PDGF-induced PI3 kinase activation and, using a PI3 kinase p110a-specific inhibitor (PIK-75), we have demonstrated that suppression of this pathway recapitulates the effects of imatinib on MSC differentiation. Furthermore, using mitogens that activate the PI3 kinase pathway, or MSCs expressing constitutively activated Akt, we have shown that activation of the PI3 kinase pathway negates the pro-adipogenic effects of imatinib. Taken together, our results suggest that imatinib increases plasma adiponectin levels by promoting adipogenesis through the suppression of PI3 kinase signalling downstream of PDGFR.
Introduction
Imatinib mesylate is a rationally designed chemotherapeutic agent that was developed to target the kinase domain of the BCR-ABL fusion protein, the causative molecular abnormality of chronic myeloid leukaemia (CML) . Imatinib binds to the inactive ATPbinding pocket of BCR-ABL, preventing ATP binding and, subsequently, catalytic activity (Druker 2004 ). Imatinib has also been shown to inhibit the function of a number of off-target kinases, resulting in a range of unique side effects that are observed in some imatinibtreated patients (Vandyke et al. 2010b) . For example, hyperphosphataemia and secondary hyperparathyroidism, observed in over 50% of imatinib-treated CML patients, are thought to relate to changes in normal bone remodelling resulting from inhibition of the macrophage colony-stimulating factor (CSF1) receptor, c-fms (CSF1R) and the platelet-derived growth factor receptor (PDGFR). At therapeutically achievable concentrations, imatinib inhibits c-fms, thereby suppressing osteoclast differentiation and function (Dewar et al. 2005 (Dewar et al. , 2006 . Conversely, imatinib is thought to stimulate osteogenesis by inhibiting PDGFR signalling in pluripotent mesenchymal stromal cells (MSCs; Fierro et al. 2007 , Fitter et al. 2008 , Jonsson et al. 2011 . Assessment of skeletal elements in CML patients, before and after imatinib treatment, has revealed an increase in trabecular bone volume and increased bone mineral density consistent with an antiosteoclastic and/or pro-osteogenic effect (Fitter et al. 2008 , Jonsson et al. 2008 , O'Sullivan et al. 2009 ).
Improved glucose metabolism has also emerged as an off-target effect of imatinib therapy in some CML patients. This side effect appears to be limited to CML patients with concurrent type 2 diabetes or those who are insulin resistant (Tsapas et al. 2008) , as no improvement in fasting glucose levels was observed in non-diabetic CML patients with normoglycaemic profiles at diagnosis (Mariani et al. 2010) . Typically, responsive patients experience a significant increase in insulin sensitivity within 3 months of commencing imatinib therapy (Breccia et al. 2004 , Veneri et al. 2005 , Gologan et al. 2009 , Mariani et al. 2010 . This improvement occurs without significant dietary or lifestyle changes, suggesting that imatinib modulates systemic insulin sensitivity. In support of this, improved glycaemic control has also been observed following imatinib treatment in animal models of diabetes. In streptozotocin-induced and spontaneous (non-obese diabetic and db/db) mouse models of diabetes, imatinib has been shown to preserve islet b-cell function, in part through the suppression of c-abl-mediated islet cell apoptosis (Hagerkvist et al. 2007 , Han et al. 2009 ). Imatinib and other inhibitors of PDGFR have also been shown to prevent and even reverse diabetes in nonobese diabetic mice through a mechanism that may involve suppression of a PDGF-induced inflammatory response (Louvet et al. 2008) . More recently, we have demonstrated that plasma levels of an adipokine, adiponectin, are elevated two-to three-fold in CML patients after 3 months of imatinib therapy . Adiponectin is known to play an important role in glucose metabolism, suggesting that this increase in adiponectin may be a mechanism whereby imatinib causes improvements in insulin sensitivity. In support of this, the increase in plasma adiponectin levels observed following imatinib treatment occurs within a similar time frame as the improvements in insulin sensitivity observed in imatinib-treated CML patients (Breccia et al. 2004 , Veneri et al. 2005 , Gologan et al. 2009 , Mariani et al. 2010 .
Adiponectin is secreted exclusively from peripheral, omental and bone marrow adipose, where its expression is regulated in response to metabolic effectors. Intramedullary adipose is derived from pluripotent MSCs that reside within the bone marrow microenvironment. Differentiation occurs in response to a variety of extrinsic factors that act to initiate or repress the transcriptional programs that govern lineage determination (Gimble 1998) . Examination of the bone marrow cellularity of CML patients before and after imatinib therapy revealed a significant increase in intramedullary adipose after 6 months of therapy ). Furthermore, we and others have observed increased adipocyte numbers in MSC cultures treated with therapeutically relevant doses of imatinib (Fierro et al. 2007 , Fitter et al. 2008 . Taken together, these findings suggest that imatinib promotes adipogenic differentiation of human MSCs.
In this study, we have shown that imatinib promotes adipogenic differentiation and adiponectin secretion from human MSCs and have identified the PI3 kinase pathway, downstream of PDGFR, as an important mechanism.
Materials and methods

Reagents
Imatinib mesylate and NVP-BEZ235 were provided by Novartis International. PI3 kinase isoform-specific inhibitors PIK-75 (p110a), TGX-221 (p110b) and IC87114 (p110d) were a kind gift from Prof. Peter Shepherd (Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, New Zealand). Pioglitazone was purchased from Cayman (Ann Arbor, MI, USA). Stock solutions of inhibitors were prepared in 100% DMSO and subsequent dilutions made in media. Unless otherwise specified, all reagents were purchased from Sigma.
MSC isolation and differentiation
MSCs were grown from bone chips recovered from posterior iliac crest bone marrow aspirates from haematologically normal human donors as described previously (Fitter et al. 2008 ) and in accordance with procedures approved by the Royal Adelaide Hospital Ethics Committee. To stimulate adipogenesis, cells were cultured in media with reduced foetal bovine serum (5% v/v) and supplemented with 100 nmol/l dexamethasone sodium phosphate (induction media) for 35 days. Conditioned media were collected from control and imatinib-treated cultures 4 days post-media change and stored at K80 8C. To identify and enumerate lipid-laden fat cells, formalinfixed cells in 96-well plates were stained with nile red (25 ng/ml) and DAPI (300 nmol/l) for 15 min. Nile red-labelled adipocytes and DAPI-stained cell nuclei were visualised using an inverted fluorescence microscope (CKX41; Olympus, Tokyo, Japan), images were captured using a colour CCD camera (4!magnification; DP20, Olympus) and adipocytes and cell nuclei were enumerated using Image J software. For mitogen experiments, induction cultures were treated with rhPDGF-BB (10 ng/ml; Prospec, Rehovot, Israel) or rhEGF (20 ng/ml; Prospec) twice weekly for 4 weeks and adipocytes were enumerated as described.
Real-time PCR
Total RNA was isolated using Trizol (Invitrogen) and real-time PCR was performed as described previously (Fitter et al. 2008) . Changes in gene expression were calculated relative to b-actin using the 2 KDC t method. Primer pairs (forward and reverse) were as follows: b-actin (ACTB), 5 0 -gatcattgctcctcctgagc-3 0 and 5 0 -gtcatagtccgcctagaagcat-3 0 ; CCAAT/enhancer binding protein, alpha (CEBPA), 5 0 -gggcaaggccaagaagtc-3 0 and 5 0 -ttgtcactggtcagctccag-3 0 ; peroxisome proliferator-activated receptor gamma 2 (PPARG), 5 0 -ctcctattgacccagaaagc-3 0 and 5 0 -tcaaaggagtgggagtggtc-3 0 ; leptin (LEP), 5 0 -ggctttggccctatcttttc-3 0 and 5 0 -accggtgactttctgtttgg-3 0 ; complement factor D (CFD), 5 0 -gacaccatcgaccacgac-3 0 and 5 0 -ccacgtcgcagagagttc-3 0 ; retinoic acid receptor responder (tazarotene induced) 2 (RARRES2), 5 0 -aagcatgcgacggctgctga-3 0 and 5 0 -agctgggaagggcgtgtcca-3 0 ; and adiponectin (ADIPOQ), 5 0 -gctgggagctgttctactgc-3 0 and 5 0 -cgatgtctcccttaggacca-3 0 .
Immunoblotting Analysis of adiponectin multimers was performed as described previously (Lara-Castro et al. 2006 . Briefly, conditioned media were electrophoresed on 8-13% non-denaturing sodium acetate PAGEs (Invitrogen) and protein complexes transferred to PVDF membrane, blocked for 2 h in 2 . 5% (w/v) blocking buffer (GE Healthcare, Little Chalfont, UK) and probed for 16 h at 4 8C using an adiponectinspecific antibody (BD Biosciences, Franklin Lakes, NJ, USA). Bound antibody was detected using an alkaline phosphatase-conjugated secondary antibody and then visualised on a Typhoon 9410 imager (GE Healthcare) in the presence of an enhanced chemifluorescence substrate. To assess total adiponectin levels, an equivalent amount of culture medium was resolved by denaturing SDS-PAGE (10% v/v), transferred to PVDF membranes and immunoblotted as described earlier.
To measure cellular proteins, cell lysates were obtained as described previously (Fitter et al. 2008 ) and equivalent amounts (50 mg) of protein separated on 10% SDS-PAGE gels and transferred to PVDF membranes. Target proteins were detected using antigenspecific antibodies (C/EBPa and PPARg2, Millipore, Billerica, MA, USA; b-actin, Sigma; HSP-90, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
PDGF pulse experiments were carried out as described previously (Fitter et al. 2008) . Briefly, MSCs were grown to 80-90% confluence in 6 cm dishes and serum deprived for 16 h. Cells were exposed to drugs (at indicated concentrations) for 1 h and then pulse stimulated with rhPDGF-BB (10 ng/ml) for 5 min. Equivalent amounts of protein (50 mg) were separated on 10% SDS-PAGE gels and transferred to PVDF membranes. Target proteins were detected using antigen-specific antibodies (phospho-Akt [Thr 308] and phospho-Erk1/2 [Thr 202/Tyr 204]; Cell Signaling, Danvers, MA, USA) as described earlier. Data are representative of results from three MSC donors.
ELISA
Adiponectin levels in cell culture conditioned media were measured using a commercial ELISA kit (R&D Systems, Minneapolis, MA, USA). Frozen conditioned media were thawed at 4 8C, centrifuged at 16 000 g for 15 min at 4 8C and adiponectin levels were determined in triplicate according to the manufacturer's instructions. The inter-plate coefficient of variation was calculated as 2 . 5-7 . 5 (%).
Cell proliferation assay
The effect of functional blocking antibodies to PDGFRa (PDGFRA) and PDGFRb (PDGFRB; 10 mg/ml; Millipore), control IgG (10 mg/ml) and imatinib (3 mmol/l) on cell survival/proliferation was assessed using WST-1 as described previously (Vandyke et al. 2010a ).
Generation of MSCs expressing myristoylated Akt
A cDNA encoding a 5 0 -src myristoylation signal in frame with mouse Akt1 (myr-Akt; a gift from Dr Naheed N Ahmed, Fox Chase Cancer Center, Philadelphia, PA, USA) was sub-cloned into pRUF-IRES-eGFP and then introduced into primary human MSCs by retroviral transduction as described previously (Isenmann et al. 2009 ). Infected cells (eGFP C ) were isolated by preparative flow cytometry and used in differentiation assays. Constitutive Akt activity was confirmed by immunoblotting using a phospho-specific p70S6K antibody (Cell Signaling) and a total p70S6K antibody (Cell Signaling).
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5; GraphPad Software, La Jolla, CA, USA). t-Tests or one-way ANOVA with Dunnett's post-tests were applied where indicated. Two-sided P values !0 . 05 were considered statistically significant.
Results
Imatinib stimulates adipogenesis
Differentiation of human MSCs into adipocytes in vitro is typically performed using a drug cocktail containing PPARg2 agonists, phosphodiesterase inhibitors and glucocorticoid, the latter being essential to drive differentiation (Gimble 1998) . To examine the effect of imatinib, we chose to use only glucocorticoid (100 nmol/l dexamethasone) to more closely emulate physiological conditions. At therapeutically relevant doses of imatinib (le Coutre et al. 2004), a dose-dependent increase in adipocyte numbers was observed ( Fig. 1A and B ). Realtime PCR was utilised to investigate transcriptional changes in genes involved in adipogenic differentiation and function. In response to imatinib, the expression of key adipogenic transcription factors CEBPA and PPARG was elevated at all time points examined (Fig. 1C ). Imatinib treatment also stimulated the expression of several adipokines including LEP, CFD and RARRES2. Most profoundly, adiponectin gene expression (ADIPOQ) was elevated up to 70-fold in imatinib-treated cultures at day 32, when compared with the vehicle control ( Fig. 1B) . Consistent with the transcriptional increases seen in response to imatinib, an increase in C/EBPa, PPARg2 and adiponectin protein levels were detected by immunoblotting ( Fig. 1D ).
Adipocytes in imatinib-treated cultures secrete high-molecular-weight adiponectin
To investigate whether adiponectin was secreted from imatinib-treated MSCs, an adiponectin-specific ELISA was used. Consistent with the gene expression studies, increased levels of secreted adiponectin were detectable in the conditioned media of MSCs cultured in the presence of imatinib for 21 days or longer ( Fig. 2A) .
To determine the nature of adiponectin complexes secreted from adipocytes in imatinib-treated MSC cultures, conditioned media were analysed by nondenaturing PAGE and western blotting. The predominant secreted form is the high-molecular-weight (HMW) complex that was evident from 17 to 21 days of culture ( Fig. 2B ).
To determine whether imatinib promotes adiponectin secretion from mature adipocyctes, MSCs were cultured under induction conditions in the presence of imatinib for 28 days to promote adipogenesis. The induction medium was then replaced with normal growth medium for 4 days after which time differentiated adipocyte cultures were stimulated with imatinib or the known PPARg2 agonists pioglitazone or indomethacin for 4 days in induction media. Conditioned media were collected and adiponectin levels were determined by ELISA. No significant increase in adiponectin secretion was observed in differentiated cultures treated with imatinib, whereas both pioglitazone and indomethacin strongly promoted adiponectin secretion when compared with the vehicle control ( Fig. 2C ).
Blocking antibodies to PDGFR promote adipogenesis and adiponectin secretion
Imatinib inhibits a number of non-receptor and receptor tyrosine kinases. These include PDGFR, which is highly expressed on mesenchymal cells. PDGF acts as a potent MSC mitogen and an inhibitor of osteogenic and adipogenic differentiation (Kratchmarova et al. 2005 , Tokunaga et al. 2008 RNA was harvested at the indicated time points, reverse transcribed into cDNA and comparative gene expression studies performed using real-time PCR. Line graphs show temporal changes in gene expression for indicated genes (meanGS.D. of triplicate measurements). (D) Protein lysates from imatinibtreated (C) and vehicle-treated (K) cultures were isolated at the indicated time points and subjected to immunoblotting using antigen-specific antibodies as indicated. BarZ500 mm.
we hypothesised that imatinib mediates its effects through inhibition of PDGFR function. To test this, functional blocking antibodies to PDGFRa and PDGFRb were included in MSC cultures under induction conditions. An antibody concentration (10 mg/ml) that inhibited cell proliferation and PDGF-induced activation of Akt equivalent to that observed following treatment with 3 mM imatinib was selected ( Fig. 3A and B ). Consistent with a role for PDGF as an inhibitor of differentiation, blocking antibodies to PDGFR promoted the formation of adipocytes in MSC cultures ( Fig. 3C and D) , and this was associated with an up-regulation of PPARg2 and adiponectin gene expression ( Fig. 3E ). Adipocytes formed in the presence of functional blocking antibodies to PDGFRa and PDGFRb were shown to secrete the HMW form of adiponectin, consistent with the effects of imatinib ( Fig. 3F and G).
Inhibition of p110a promotes adipogenesis and adiponectin secretion
In mesenchymal cells, stimulation with PDGF has been shown to strongly activate the PI3 kinase pathway, as evidenced by the phosphorylation of the regulatory and catalytic subunits of class I PI3 kinase family members and downstream effector molecules such as Akt (Kratchmarova et al. 2005) . Suppression of PI3 kinase using pharmacological inhibitors has been shown to promote MSC differentiation (Kratchmarova et al. 2005 , Fitter et al. 2008 , Martin et al. 2010 ), suggesting that this pathway is important for transducing the inhibitory effects of PDGF on MSC differentiation. Consistent with this hypothesis, imatinib is a potent inhibitor of PDGF-induced PI3 kinase activation, as evidenced by a dose-dependent decrease in the phosphorylation of Akt (Fig. 4A) . By contrast, PDGFinduced Erk activation, a measure of MAPK activity, is not affected by imatinib treatment (Fig. 4A) .
In light of the inhibitory effect of imatinib on PDGFinduced PI3 kinase activation, we hypothesised that an inhibitor of the catalytic subunit of PI3 kinase would promote adipogenesis. As MSCs express PI3 kinase subunits p110a, p110b and p110d (data not shown), the isoform-specific inhibitors BEZ235, PIK-75, TGX-221 and IC87114 were tested initially to assess the role of each subunit in PDGF-induced Akt activation. Only PIK-75, an inhibitor of p110a (Chaussade et al. 2007 ) and BEZ235, a pan class I inhibitor (Serra et al. 2008) , were found to inhibit PDGF-induced Akt phosphorylation (Fig. 4B ). PIK-75 inhibits PDGF-induced Akt phosphorylation dose dependently (Fig. 4C) with an IC 50 of 10 nM.
Consistent with the results obtained for imatinib and functional blocking PDGFR antibodies, PIK-75 was shown to dose dependently promote adipocyte formation under induction conditions ( Fig. 4D and E) . Similarly, high levels of secreted HMW and LMW adiponectin complexes were detected in cultures treated with PIK-75 for 18 days or more, when compared with vehicle-treated control cultures ( Fig. 4F and G) .
Mitogens that activate PI3 kinase negate the proadipogenic effects of imatinib but not PIK-75
To further investigate the role of the PI3 kinase pathway in MSC differentiation, we examined the effects of adding exogenous mitogens to imatinib or PIK-75-treated MSC cultures under induction conditions. Both PDGF and EGF activate the PI3 kinase pathway in human MSCs (Kratchmarova et al. 2005) . Consistent with previous reports (Artemenko et al. 2005 , Gagnon et al. 2009 ), we found that addition of growth factors alone completely inhibited glucocorticoid-induced adipogenesis (Fig. 5A and B) . In the presence of imatinib, PDGF had no effect on imatinibmediated adipogenesis whereas EGF inhibited the imatinib response ( Fig. 5A and B) . In contrast, PIK-75 promoted adipogenesis, albeit to a lesser extent, in the presence of either PDGF or EGF ( Fig. 5A and B ), suggesting that the PI3 kinase pathway is important for transducing the inhibitory effects of mitogens on MSC differentiation.
Constitutive activation of Akt negates the effects of imatinib on MSC differentiation
Having established a signalling pathway that links imatinib with MSC differentiation, we sought to confirm our findings using a genetic approach. Akt is the primary effector molecule of the PI3 kinase pathway, and its activation is suppressed by imatinib in response to PDGF stimulation. It therefore follows that constitutive activation of Akt would negate the pro-adipogenic effects of imatinib. To test this, MSC cultures that express constitutively activated Akt (myr-Akt) or vector only were treated with imatinib and their ability to differentiate into adipocytes was measured. To confirm activation of Akt, the phosphorylation status of p70S6K, an Akt effector S FITTER and others . Imatinib promotes adipogenesis molecule (Hay & Sonenberg 2004) , was assessed. Hyperphosphorylated p70S6K was detected in immunoblots of proteins isolated from cells expressing myr-Akt, when compared with vector-only control cells lysates (Fig. 6A) . Under induction conditions, imatinib promoted adipogenic differentiation of vector control cells but failed to promote adipogenesis in hMSCs expressing myr-Akt (Fig. 6B) . By contrast, indomethacin, a PPAR agonist (Lehmann et al. 1997) , promoted adipogenesis in both control and myr-Akt-expressing cells. 
Discussion
Here, we demonstrate that therapeutically relevant concentrations of imatinib promote the differentiation of human MSCs into adipocytes, which in turn secrete the HMW form of adiponectin. Imatinib failed to promote adiponectin secretion from mature adipocytes, suggesting that imatinib does not promote adiponectin secretion through a direct effect on adiponectin gene expression but rather indirectly through an effect on adipocyte numbers. MSCs are pluripotent and lineage specificity can be orchestrated in vitro using a combination of ligands that act directly, or indirectly, to drive lineage-specific transcription factors (Pittenger et al. 1999) . Crucial to this response is the addition of glucocorticoid that acts to prime cells to be responsive to differentiation signals (Gimble 1998) . Treatment of MSCs with imatinib alone is sufficient to stimulate adipogenesis in glucocorticoidtreated cells, as evidenced by a temporal increase in key adipogenic transcription factors C/EBPa and PPARg2, the accumulation of lipid-laden vacuoles and secretion of the adipokine adiponectin. Glucocorticoid-treated cells appear highly sensitive to the pro-adipogenic effects of imatinib, resulting in adipogenic differentiation of MSCs at hydrocortisone concentrations well below physiological levels (5 nmol/l; data not shown). As the reductase required to regenerate active cortisone in vivo, 11b-hydroxysteroid dehydrogenase type I (11bHSD), is highly expressed in MSCs and bone cells (Justesen et al. 2004) , bone marrow-synthesised steroid and imatinib could act locally on MSC populations to drive adipogenic differentiation.
Previous studies have demonstrated that PDGF is a potent MSC mitogen that has been shown to inhibit MSC differentiation (Hock & Canalis 1994 , Kubota et al. 2002 , Chaudhary et al. 2004 , Kratchmarova et al. 2005 . Imatinib is a potent PDGFR inhibitor (Buchdunger et al. 2000) , suggesting that imatinib mediates its proadipogenic effects through inhibition of PDGFR. In support of this, we have shown that functional blocking antibodies to PDGFR promote adipogenesis and adiponectin secretion when used at concentrations that suppress cell proliferation and PDGF-induced Akt activation similar to that achieved with imatinib. We therefore hypothesise that, in cultures treated with physiological levels of glucocorticoid alone, the basal adipogenic response to glucocorticoid is suppressed by PDGF, which is present in bovine serum, and is secreted in an autocrine and/or paracrine fashion by MSCs (Bonner 2010 ). Addition of imatinib or functional blocking antibodies ameliorates this inhibitory effect allowing differentiation to proceed unabated.
Studies using mouse 3T3-L1 pre-adipocytes and human subcutaneous adipose-derived stem cells have suggested that PDGF-induced activation of PKCa and IKKb mediates the inhibitory effect of PDGF on adipogenesis (Artemenko et al. 2005 , Gagnon et al. 2009 ). However, we failed to detect activation of these pathways in response to PDGF in bone marrow-derived MSCs (data not shown), which may be due to cell-type differences or the PDGF isoform used. In hMSCs, PDGF strongly activates the PI3 kinase pathway and previous studies have suggested that the anti-differentiative effects of PDGF could be inhibited using PI3 kinase inhibitors such as Wortmannin and LY94002 (Kratchmarova et al. 2005 , Fitter et al. 2008 , Martin et al. 2010 . Consistent with this view, we have demonstrated that imatinib is a potent inhibitor of PDGF-induced Akt phosphorylation, a major substrate of the PI3 kinase pathway. Furthermore, the pro-adipogenic effect of imatinib, but not that of indomethacin, was negated by BarZ500 mm.
S FITTER and others . Imatinib promotes adipogenesis constitutive activation of Akt. Addition of exogenous EGF to MSC cultures also inhibited imatinib-induced adipogenesis. EGF activates the PI3 kinase pathway in MSCs, albeit to a lesser extent than PDGF (Kratchmarova et al. 2005 ) and, unlike PDGFR, EGFR is insensitive to imatinib (Buchdunger et al. 2000) . The anti-differentiative effects of PI3 kinase signalling on hMSCs was further demonstrated using PIK-75, a selective inhibitor of p110a, the catalytic subunit of the obligate heterodimer type I PI3 kinase. PIK-75 promotes hMSC adipogenic differentiation and adiponectin secretion even in the presence of exogenous growth factors. Unlike imatinib, PIK-75 inhibits PI3 kinase activity irrespective of the nature of the mitogen. At the concentrations used in this study, PIK-75, imatinib and anti-PDGFR antibodies inhibit proliferation and suppress the PI3 kinase pathway.
While inhibition of proliferation may be important for the pro-adipogenic effects, studies using g-irradiation show that it is not sufficient to promote differentiation under induction conditions (data not shown). Further analysis of Akt substrates that are suppressed or activated in PIK-75-and imatinib-treated MSCs is required to gain further mechanistic insight. Our hypothesis that inhibition of PI3 kinase, downstream of PDGFR, promotes adipogenic differentiation of bone marrow-derived hMSCs is in contrast to a large body of data demonstrating an essential role for PI3 kinase signalling in adipogenesis in murine cells. Much of this evidence has been obtained using the wellcharacterised murine 3T3-L1 cell line (derived from white adipose tissue), which differentiates into adipocytes in response to insulin. This insulin-mediated differentiation process can be blocked using PI3 kinase inhibitors Wortmannin and LY94002 and by overexpression of a dominant-negative p85 (Sakaue et al. 1998 , Xu & Liao 2004 . Furthermore, over-expression of constitutively active forms of PI3 kinase or Akt has been shown to recapitulate the effects of insulin on Glut4 translocation and adipogenic differentiation in these cells (Kohn et al. 1996 , Magun et al. 1996 . Insulin and the PI3 kinase pathway has also been demonstrated to be essential for adipogenic differentiation in primary mouse cells, as demonstrated by a complete lack of adipocytes and complete abrogation of PI3 kinase activity in murine embryonic fibroblasts (MEFs) isolated from insulin receptor substrate (Irs1 and Irs2) knockout mice (Miki et al. 2001 ). Furthermore, MEFs isolated from p110a null mice fail to differentiate into adipocytes in response to insulin (Zhao et al. 2006) . Important distinctions that may account for our findings relate to the intrinsic responsiveness of hMSCs to insulin signalling and to the nature of the proadipogenic stimuli used in our study. Unlike mouse 3T3-L1 cells, hMSCs do not differentiate into adipocytes in response to insulin or insulin-like growth factor 1 (IGF1) alone, instead requiring glucocorticoid to prime the cells to be responsive to pro-adipogenic stimuli (Greenberger 1979 , Scavo et al. 2004 . In light of this, we have used a differentiation media solely consisting of physiological levels of glucocorticoid to enable us to measure adipogenic responses in the absence of other known pro-adipogenic stimuli including insulin and IGF1. It is therefore possible that PI3 kinase may play a lesser role in transducing differentiation signals in the absence of insulin or IGF1 signalling, as seen in our system. Alternatively, the pro-adipogenic effects of imatinib and PIK-75 may be due to dysregulation of Akt as is seen in MSCs isolated from mice lacking the regulatory subunit of PI3 kinase, p85a. Loss of p85a results in the down-regulation of p110a and hyperactivation of Akt, which induces adipogenesis (Wu et al. 2011) . This result suggests that PIK-75 may promote adipogenesis by uncoupling the normal regulation of Akt. However, our results indicate that Akt phosphorylation is decreased during PIK-75-or imatinib-mediated differentiation of hMSCs ( Supplementary Figure 1 , see section on supplementary data given at the end of this article), indicating that Akt signalling is not hyperactivated in response to these drugs under induction conditions. PI3 kinase-independent mechanisms of adipogenic differentiation have also been described. Suppression of MAPK activity in hMSCs has been shown to promote adipogenesis in the absence of insulin and IGF1 signalling ( Jaiswal et al. 2000) . However, we failed to detect a decrease in the activation status of the MAPK substrates Erk1/2 in the presence of imatinib or PIK-75 during differentiation ( Supplementary Figure 1) , suggesting that suppression of the MAPK pathway was not responsible for the pro-adipogenic effect of these inhibitors. Conversely, p38 MAPK signalling has been proposed as a pro-adipogenic stimuli, as inhibition of p38 has been shown to negate adipogenic differentiation in hMSCs (Aouadi et al. 2007 ). However, imatinib suppresses PDGF-induced p38 activation (Fitter et al. 2008 ), suggesting that activation of p38 MAPK is an unlikely mechanism by which imatinib or PIK-75 promotes adipogenesis.
In cultures treated with PIK-75 or imatinib, the HMW form of adiponectin is the predominant form secreted. Several lines of evidence suggest that the HMW form is the most active with respect to modulating insulin sensitivity (Waki et al. 2003 , Lara-Castro et al. 2006 . Consistent with this, analysis of plasma adiponectin complexes in CML patients, before and after 3 months of imatinib therapy, revealed a significant increase in the level of HMW complexes . In humans, adiponectin levels correlate negatively with insulin resistance and metabolic syndrome, with low adiponectin levels being associated with a higher risk of type 2 diabetes (Li et al. 2009 ). Thiazolidinedione compounds, a class of anti-diabetic drugs that improve systemic insulin sensitivity, are thought to work, at least in part, by promoting the formation of small adipocytes that secrete high levels of HMW adiponectin , Phillips et al. 2003 , Nawrocki et al. 2006 .
In summary, we have identified the PI3 kinase pathway downstream of PDGFR as important in mesenchymal cell differentiation. Inhibition of this pathway, using imatinib or PIK-75, promotes adipogenesis and secretion of HMW adiponectin. In light of this, we hypothesise that inhibition of PDGFR signalling in imatinib-treated CML patients results in increased intramedullary adipogenesis and, subsequently, in an increase in circulating adiponectin levels. These increased adiponectin levels may account for the improvements in glucose and lipid metabolism observed in some imatinib-treated CML patients with concurrent type 2 diabetes.
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